Supplementary file 1_Cost–utility and price threshold analysis of sacituzumab tirumotecan

Limin Huo authored a supplementary document analyzing the economic value of sacituzumab tirumotecan for metastatic triple-negative breast cancer in China. The analysis uses a state-transition model to estimate lifetime costs and quality-adjusted life-years, comparing the drug to single-agent chemotherapy. The document, last updated in April 2026, includes results from cost-utility and price threshold analyses under different payment contexts.

Use Cases

• Conducting cost-effectiveness analyses based on the Markov model and willingness-to-pay thresholds described.
• Evaluating drug pricing strategies for oncology based on the price threshold and patient assistance program scenarios.
• Researching healthcare policy and reimbursement for metastatic breast cancer treatments in China based on the regional economic analysis.

Strengths

• Document is 1.9 MB in size, indicating a substantive analysis.
• Analysis is based on clinical efficacy data from a phase III randomized trial.
• Includes specific price reduction targets (48.3% and 34.9% of list price) for cost-effectiveness.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The primary data format is DOCX, which may require conversion for computational analysis.

Provenance

Source

figshare

Collection Method

Modeling study using clinical trial data and economic parameters.

Time Range

Analysis likely reflects data and economic conditions circa 2026.

Freshness

Last updated 2026-04 23 04:21:54; freshness should be verified.

Geography

China, with specific focus on national and economically underdeveloped regions.